Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with (177)Lu-PSMA and Combined (225)Ac- and (177)Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation

Purpose: PSMA-targeted radioligand therapy (PRLT) is a promising treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). However, a high uptake of the radiopharmaceutical in the salivary glands (SG) can lead to xerostomia and becomes dose-limiting for (225)Ac-PSMA...

Descripción completa

Detalles Bibliográficos
Autores principales: Langbein, Thomas, Kulkarni, Harshad R., Schuchardt, Christiane, Mueller, Dirk, Volk, Gerd Fabian, Baum, Richard P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406477/
https://www.ncbi.nlm.nih.gov/pubmed/36010276
http://dx.doi.org/10.3390/diagnostics12081926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406477/
https://www.ncbi.nlm.nih.gov/pubmed/36010276
http://dx.doi.org/10.3390/diagnostics12081926

Ejemplares similares